Could you explain the science and engineering behind your patented “OZ Inside™” ultrasound miniaturization platform?

The patented OZ Inside™ ultrasound miniaturization platform is the technological core that powers ZetrOZ Systems sustained acoustic medicine devices. This innovation brings together precision engineering, biomedical science, and intelligent design to deliver continuous therapeutic ultrasound in a small, portable, and user-friendly form. The platform uses proprietary algorithms and advanced circuitry to precisely control acoustic frequency, intensity, and waveform, ensuring optimal tissue penetration and consistent therapeutic output. By miniaturizing the ultrasound components, ZetrOZ has made it possible to deliver clinical-grade therapy in a wearable format—eliminating the need for bulky, clinic-based systems. The engineering team has also focused on energy efficiency, patient comfort, and usability, integrating long-lasting batteries, flexible materials, and medical-grade adhesives for everyday wear. The result is a platform that transforms proven ultrasound science into a practical, home-based recovery tool—providing continuous, non-invasive treatment that promotes tissue regeneration, reduces inflammation, and accelerates healing.

What sets sustained acoustic medicine (sam^®) apart from traditional therapeutic ultrasound?

Sustained acoustic medicine (sam^®) stands apart from traditional therapeutic ultrasound by fundamentally changing how treatment is delivered and experienced. Conventional ultrasound is typically administered in short, clinic-based sessions lasting only a few minutes, requiring repeated visits and limiting treatment accessibility. In contrast, sam^® leverages the patented OZ Inside™ platform to provide continuous, long-duration therapy in a wearable device that patients can comfortably use at home. This extended application allows ultrasound energy to penetrate deep into soft tissue over several hours, amplifying its therapeutic effects improving circulation, reducing inflammation, and accelerating natural tissue repair. The drug-free, non-invasive approach not only supports recovery from acute injuries but also offers consistent relief for chronic conditions such as arthritis, tendonitis, and overuse injuries common in athletes. By combining portability, ease of use, and clinical effectiveness, sam^® bridges the gap between professional care and daily self-management, empowering patients with a reliable tool to enhance healing and improve quality of life.

What emerging technologies or unmet clinical needs do you see as the next frontier for your innovation pipeline?

The next frontier for ZetrOZ Systems lies in advancing non-invasive, drug-free solutions that address unmet needs in pain management, recovery, and preventative care. As healthcare continues to shift toward personalized and technology-enabled treatments, ZetrOZ is focusing its innovation pipeline on expanding sustained acoustic medicine into new clinical domains particularly chronic musculoskeletal disorders, post-surgical rehabilitation, and long-term injury prevention for active individuals. Future developments include next-generation wearable devices with enhanced miniaturization, longer battery life, and smart connectivity features that integrate with digital health platforms. These advancements will enable real-time monitoring, data-driven insights, and individualized therapy settings to optimize outcomes and patient engagement. By merging biomedical engineering with digital innovation, ZetrOZ aims to create a seamless continuum of care where treatment is precise, proactive, and tailored to each user’s recovery journey. The ultimate goal is to make effective, evidence-based healing accessible anytime, anywhere, empowering people to take charge of their health.

How do these philanthropic efforts align with your broader mission to reach 100 million patients?

Philanthropy plays a vital role in advancing ZetrOZ Systems’ broader mission to reach and improve the lives of 100 million patients worldwide. By extending access to sustained acoustic medicine (sam^®) therapy beyond traditional markets, these efforts ensure that effective, non-invasive treatment is available to individuals who may otherwise face barriers due to cost, geography, or limited healthcare infrastructure. Through partnerships with community health organizations, rehabilitation centers, and global advocacy groups, ZetrOZ is able to bring its wearable therapeutic technology to underserved populations—empowering people to take charge of their recovery and long-term wellness. These initiatives not only expand access but also reinforce the company’s commitment to health equity and patient empowerment. Every philanthropic partnership contributes to building a more inclusive model of care, where innovative, science-backed solutions reach those who need them most. In doing so, ZetrOZ continues to move closer to its ambitious goal of positively impacting 100 million lives.

What challenges and opportunities do you face in producing non-invasive, drug-free therapeutic devices?

Producing non-invasive, drug-free therapeutic devices presents both complex challenges and exciting opportunities for innovation. One of the primary hurdles lies in balancing advanced biomedical engineering with everyday usability—ensuring that wearable devices maintain consistent, clinically proven efficacy while remaining comfortable, safe, and simple for patients to operate at home. Achieving this requires extensive R&D, precision tuning of ultrasound parameters for long-duration therapy, and ongoing clinical validation to meet rigorous medical standards. Miniaturizing high-performance ultrasound technology into compact, portable formats also demands continuous breakthroughs in materials science, power management, and device durability. Yet, these challenges serve as catalysts for progress. They enable ZetrOZ Systems to distinguish sam^® as a reliable, evidence-based alternative to pharmaceuticals and invasive procedures. Each engineering advancement enhances accessibility, patient independence, and long-term health outcomes—aligning with ZetrOZ’s vision to transform pain management and rehabilitation through safe, sustainable, and science-driven innovation.

As a leader in sustained acoustic medicine, how do you see the market evolving over the next 5 years?

The market for non-invasive, drug-free therapeutic devices is poised for rapid growth. Patients are seeking treatments that are effective, convenient, and accessible outside of traditional clinic settings. Clinicians and health systems are increasingly recognizing the value of long-duration, home-use therapies that improve outcomes and reduce healthcare burdens. Over the next five years, we anticipate broader adoption of wearable ultrasound technologies, expansion into new clinical areas, and increased integration with digital health platforms, ultimately transforming how musculoskeletal care is delivered.

“Wearable, Non-Invasive, and Science-Backed – Empowering Patients Every Day.”

“Transforming Pain Management Through Innovation and Accessibility.”